Boehringer Ingelheim International GmbH will likely need to conduct another trial for empagliflozin after the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee voted 14-2 that the benefits do not outweigh the risks as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes mellitus.
Many panelists at the 13 November meeting said the existing data were promising, but they also felt that a larger...





